TeleMedVET (TMV) is an innovative veterinary diagnostics company revolutionising equine health and performance through cutting-edge technology. Founded by experts in nuclear medicine and horse racing, TMV is pioneering the integration of human-grade diagnostic capabilities into veterinary care. The company’s core innovation lies in its biomarker-based blood test and advanced imaging tools, which enable the early detection and prevention of skeletal injuries in racehorses. Backed by peer-reviewed research and collaborations with top racing organisations, TMV’s solution combines a handheld blood test device and CT/SPECT imaging to monitor bone fatigue and flag at-risk horses, well before injury occurs. This preventative approach supports better training decisions and significantly enhances animal welfare and racing performance.
TMV’s business model is underpinned by dual revenue streams: upfront sales of diagnostic kits and consumables, and ongoing income from the deployment and servicing of CT/SPECT imaging units in veterinary clinics and training centres. With strong industry partnerships, published scientific validation and minimal regulatory hurdles compared to human healthcare, TMV is positioned as a first-mover in equine diagnostics. Its technology offers unparalleled insight and predictive power, delivering both commercial returns and a tangible impact on animal welfare in the global racing industry.
